Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 459

1.

Prevalence of and Preparedness to Address Inappropriate Sexual Behavior from Patients During Psychiatry Training: a Pilot Study.

Michael S, Chen X, Raymond E, Capasso R.

Acad Psychiatry. 2019 Aug 6. doi: 10.1007/s40596-019-01094-y. [Epub ahead of print]

PMID:
31388946
2.

The challenge of inclusion for older people with impairments: Insights from a stigma-based analysis.

Raymond É.

J Aging Stud. 2019 Jun;49:9-15. doi: 10.1016/j.jaging.2019.03.001. Epub 2019 Mar 15.

PMID:
31229222
3.

Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.

Astorgues-Xerri L, Vázquez R, Odore E, Rezai K, Kahatt C, Mackenzie S, Bekradda M, Coudé MM, Dombret H, Gardin C, Lokiec F, Raymond E, Noel K, Cvitkovic E, Herait P, Bertoni F, Riveiro ME.

Leuk Lymphoma. 2019 Jun 17:1-4. doi: 10.1080/10428194.2019.1617860. [Epub ahead of print] No abstract available.

PMID:
31204545
4.

TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States.

Raymond E, Chong E, Winikoff B, Platais I, Mary M, Lotarevich T, Castillo PW, Kaneshiro B, Tschann M, Fontanilla T, Baldwin M, Schnyer A, Coplon L, Mathieu N, Bednarek P, Keady M, Priegue E.

Contraception. 2019 Sep;100(3):173-177. doi: 10.1016/j.contraception.2019.05.013. Epub 2019 Jun 4.

PMID:
31170384
5.

Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors.

Fazio N, Martini JF, Croitoru AE, Schenker M, Li S, Rosbrook B, Fernandez K, Tomasek J, Thiis-Evensen E, Kulke M, Raymond E.

Future Oncol. 2019 Jun;15(17):1997-2007. doi: 10.2217/fon-2018-0934. Epub 2019 May 14.

6.

Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5).

Ahlberg J, Giragossian C, Li H, Myzithras M, Raymond E, Caviness G, Grimaldi C, Brown SE, Perez R, Yang D, Kroe-Barrett R, Joseph D, Pamulapati C, Coble K, Ruus P, Woska JR, Ganesan R, Hansel S, Mbow ML.

MAbs. 2019 Jul;11(5):956-964. doi: 10.1080/19420862.2019.1615345. Epub 2019 Jun 4.

7.

Cerebral inducible nitric oxide synthase protein expression in microglia, astrocytes and neurons in Trypanosoma brucei brucei-infected rats.

Cespuglio R, Amrouni D, Raymond EF, Bouteille B, Buguet A.

PLoS One. 2019 Apr 17;14(4):e0215070. doi: 10.1371/journal.pone.0215070. eCollection 2019.

8.

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.

Faivre S, Santoro A, Kelley RK, Gane E, Costentin CE, Gueorguieva I, Smith C, Cleverly A, Lahn MM, Raymond E, Benhadji KA, Giannelli G.

Liver Int. 2019 Aug;39(8):1468-1477. doi: 10.1111/liv.14113. Epub 2019 Jun 3.

PMID:
30963691
9.

ITPase deficiency causes a Martsolf-like syndrome with a lethal infantile dilated cardiomyopathy.

Handley MT, Reddy K, Wills J, Rosser E, Kamath A, Halachev M, Falkous G, Williams D, Cox P, Meynert A, Raymond ES, Morrison H, Brown S, Allan E, Aligianis I, Jackson AP, Ramsahoye BH, von Kriegsheim A, Taylor RW, Finch AJ, FitzPatrick DR.

PLoS Genet. 2019 Mar 11;15(3):e1007605. doi: 10.1371/journal.pgen.1007605. eCollection 2019 Mar.

10.

GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.

Brun S, Bassissi F, Serdjebi C, Novello M, Tracz J, Autelitano F, Guillemot M, Fabre P, Courcambeck J, Ansaldi C, Raymond E, Halfon P.

Invest New Drugs. 2019 Feb 19. doi: 10.1007/s10637-019-00741-3. [Epub ahead of print]

PMID:
30778887
11.

Reducing Rape-Related Attitudes Utilizing a Cognitive Dissonance Paradigm.

Steinmetz SE, Gray MJ, Raymond EM.

Violence Against Women. 2019 Feb 7:1077801218824999. doi: 10.1177/1077801218824999. [Epub ahead of print]

PMID:
30729867
12.

Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.

Valle JW, Borbath I, Rosbrook B, Fernandez K, Raymond E.

Future Oncol. 2019 Apr;15(11):1219-1230. doi: 10.2217/fon-2018-0882. Epub 2019 Jan 31.

13.

Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.

Evrard D, Szturz P, Tijeras-Raballand A, Astorgues-Xerri L, Abitbol C, Paradis V, Raymond E, Albert S, Barry B, Faivre S.

Oral Oncol. 2019 Jan;88:29-38. doi: 10.1016/j.oraloncology.2018.10.040. Epub 2018 Nov 20. Review.

PMID:
30616794
14.

Efficacy of Misoprostol Alone for First-Trimester Medical Abortion: A Systematic Review.

Raymond EG, Harrison MS, Weaver MA.

Obstet Gynecol. 2019 Jan;133(1):137-147. doi: 10.1097/AOG.0000000000003017.

PMID:
30531568
15.

Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice With Chronic Intestinal Inflammation.

Scheibe K, Kersten C, Schmied A, Vieth M, Primbs T, Carlé B, Knieling F, Claussen J, Klimowicz AC, Zheng J, Baum P, Meyer S, Schürmann S, Friedrich O, Waldner MJ, Rath T, Wirtz S, Kollias G, Ekici AB, Atreya R, Raymond EL, Mbow ML, Neurath MF, Neufert C.

Gastroenterology. 2019 Mar;156(4):1082-1097.e11. doi: 10.1053/j.gastro.2018.11.029. Epub 2018 Nov 16.

PMID:
30452921
16.

An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients.

Bassolas-Molina H, Raymond E, Labadia M, Wahle J, Ferrer-Picón E, Panzenbeck M, Zheng J, Harcken C, Hughes R, Turner M, Smith D, Calderón-Gómez E, Esteller M, Carrasco A, Esteve M, Dotti I, Corraliza AM, Masamunt MC, Arajol C, Guardiola J, Ricart E, Nabozny G, Salas A.

Front Immunol. 2018 Oct 22;9:2307. doi: 10.3389/fimmu.2018.02307. eCollection 2018.

17.

Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study.

Delmotte JB, Beaussier H, Auzeil N, Massicot F, Laprévote O, Raymond E, Coudoré F.

Cancer Treat Res Commun. 2018;17:31-36. doi: 10.1016/j.ctarc.2018.10.002. Epub 2018 Oct 10.

PMID:
30343217
18.

Safety and Tolerability of Overdosed Artificial Tears by Abraded Rabbit Corneas.

Daull P, Raymond E, Feraille L, Garrigue JS.

J Ocul Pharmacol Ther. 2018 Oct 12. doi: 10.1089/jop.2018.0040. [Epub ahead of print]

19.

Study protocol for the Australian autism biobank: an international resource to advance autism discovery research.

Alvares GA, Dawson PA, Dissanayake C, Eapen V, Gratten J, Grove R, Henders A, Heussler H, Lawson L, Masi A, Raymond E, Rose F, Wallace L, Wray NR, Whitehouse AJO; Australian Autism Biobank team.

BMC Pediatr. 2018 Aug 27;18(1):284. doi: 10.1186/s12887-018-1255-z.

20.

Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position.

Ciccolini J, Del Re M, Danesi R, Milano G, Schellens JHM, Raymond E.

Ann Oncol. 2018 Sep 1;29(9):1893-1894. doi: 10.1093/annonc/mdy258. No abstract available.

PMID:
30032203
21.

Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.

Raymond E, Kulke MH, Qin S, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu JM, Croitoru AE, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein PE, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Sufliarsky J, Khan GN, Morizane C, Galdy S, Khosravan R, Fernandez KC, Rosbrook B, Fazio N.

Neuroendocrinology. 2018;107(3):237-245. doi: 10.1159/000491999. Epub 2018 Jul 10.

PMID:
29991024
22.

Workloads of Competitive Surfing: Work-to-Relief Ratios, Surf-Break Demands, and Updated Analysis.

Farley ORL, Secomb JL, Raymond ER, Lundgren LE, Ferrier BK, Abbiss CR, Sheppard JM.

J Strength Cond Res. 2018 Oct;32(10):2939-2948. doi: 10.1519/JSC.0000000000002659.

PMID:
29912078
23.

Morphomic Malnutrition Score: A Standardized Screening Tool for Severe Malnutrition in Adults.

Lee C, Raymond E, Derstine BA, Glazer JM, Goulson R, Rajasekaran A, Cherry-Bukowiec J, Su GL, Wang SC.

JPEN J Parenter Enteral Nutr. 2018 Nov;42(8):1263-1271. doi: 10.1002/jpen.1175. Epub 2018 May 22.

PMID:
29786877
24.

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

Van Cutsem E, Hidalgo M, Canon JL, Macarulla T, Bazin I, Poddubskaya E, Manojlovic N, Radenkovic D, Verslype C, Raymond E, Cubillo A, Schueler A, Zhao C, Hammel P.

Int J Cancer. 2018 Oct 15;143(8):2053-2064. doi: 10.1002/ijc.31603. Epub 2018 Aug 9.

PMID:
29756206
25.

A direct-to-patient telemedicine abortion service in Australia: Retrospective analysis of the first 18 months.

Hyland P, Raymond EG, Chong E.

Aust N Z J Obstet Gynaecol. 2018 Jun;58(3):335-340. doi: 10.1111/ajo.12800. Epub 2018 Mar 30.

PMID:
29603139
26.

Low-sensitivity urine pregnancy testing to assess medical abortion outcome: A systematic review.

Raymond EG, Shochet T, Bracken H.

Contraception. 2018 Jul;98(1):30-35. doi: 10.1016/j.contraception.2018.03.013. Epub 2018 Mar 10. Review.

PMID:
29534996
27.

Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.

Pellat A, Dreyer C, Couffignal C, Walter T, Lombard-Bohas C, Niccoli P, Seitz JF, Hentic O, André T, Coriat R, Faivre S, Zappa M, Ruszniewski P, Pote N, Couvelard A, Raymond E.

Neuroendocrinology. 2018;107(1):24-31. doi: 10.1159/000487237. Epub 2018 Mar 8.

PMID:
29518779
28.

Self-assessment of medical abortion outcome using symptoms and home pregnancy testing.

Raymond EG, Tan YL, Grant M, Benavides E, Reis M, Sacks DN, Hannum C, Frapp S, Weaver MA.

Contraception. 2018 Apr;97(4):324-328. doi: 10.1016/j.contraception.2017.12.004. Epub 2017 Dec 11.

PMID:
29242085
29.

E3 Ubiquitin Ligase RNF125 Activates Interleukin-36 Receptor Signaling and Contributes to Its Turnover.

Saha SS, Caviness G, Yi G, Raymond EL, Mbow ML, Kao CC.

J Innate Immun. 2018;10(1):56-69. doi: 10.1159/000481210. Epub 2017 Nov 25.

30.

Simplified medical abortion screening: a demonstration project.

Raymond EG, Tan YL, Comendant R, Sagaidac I, Hodorogea S, Grant M, Sanhueza P, Van Pratt E, Gillespie G, Boraas C, Weaver MA, Platais I, Bousieguez M, Winikoff B.

Contraception. 2018 Apr;97(4):292-296. doi: 10.1016/j.contraception.2017.11.005. Epub 2017 Nov 21.

PMID:
29170088
31.

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.

Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz HJ, Raoul JL, Meropol NJ, Lombard-Bohas C, Posey J, Faivre S, Raymond E, Valle JW.

Br J Cancer. 2018 Jan;118(2):181-188. doi: 10.1038/bjc.2017.402. Epub 2017 Nov 21.

32.

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data.

Szturz P, Budíková M, Vermorken JB, Horová I, Gál B, Raymond E, de Gramont A, Faivre S.

Oral Oncol. 2017 Nov;74:68-76. doi: 10.1016/j.oraloncology.2017.09.009. Epub 2017 Sep 27. Review.

PMID:
29103754
33.

Exploring the feasibility of obtaining mifepristone and misoprostol from the internet.

Murtagh C, Wells E, Raymond EG, Coeytaux F, Winikoff B.

Contraception. 2018 Apr;97(4):287-291. doi: 10.1016/j.contraception.2017.09.016. Epub 2017 Oct 11.

34.

Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.

Bouattour M, Raymond E, Qin S, Cheng AL, Stammberger U, Locatelli G, Faivre S.

Hepatology. 2018 Mar;67(3):1132-1149. doi: 10.1002/hep.29496. Epub 2018 Feb 1. Review.

35.

Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.

Ganesan R, Raymond EL, Mennerich D, Woska JR Jr, Caviness G, Grimaldi C, Ahlberg J, Perez R, Roberts S, Yang D, Jerath K, Truncali K, Frego L, Sepulveda E, Gupta P, Brown SE, Howell MD, Canada KA, Kroe-Barrett R, Fine JS, Singh S, Mbow ML.

MAbs. 2017 Oct;9(7):1143-1154. doi: 10.1080/19420862.2017.1353853. Epub 2017 Jul 20.

36.

Physiological and pathophysiological control of synaptic GluN2B-NMDA receptors by the C-terminal domain of amyloid precursor protein.

Pousinha PA, Mouska X, Raymond EF, Gwizdek C, Dhib G, Poupon G, Zaragosi LE, Giudici C, Bethus I, Pacary E, Willem M, Marie H.

Elife. 2017 Jul 6;6. pii: e25659. doi: 10.7554/eLife.25659.

37.

Optimum Tools for Predicting Clinical Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Systematic Review of Prognostic Accuracy and Validity.

Campbell JM, Raymond E, O'Callaghan ME, Vincent AD, Beckmann KR, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, Borg M, Moretti KL.

Clin Genitourin Cancer. 2017 Oct;15(5):e827-e834. doi: 10.1016/j.clgc.2017.06.001. Epub 2017 Jun 8. Review.

PMID:
28666689
38.

Tools for predicting patient-reported outcomes in prostate cancer patients undergoing radical prostatectomy: a systematic review of prognostic accuracy and validity.

O'Callaghan ME, Raymond E, Campbell J, Vincent AD, Beckmann K, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, Borg M, Moretti K.

Prostate Cancer Prostatic Dis. 2017 Dec;20(4):378-388. doi: 10.1038/pcan.2017.28. Epub 2017 Jun 6. Review.

PMID:
28585573
39.

Tools for Predicting Clinical and Patient-reported Outcomes in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Systematic Review of Prognostic Accuracy and Validity.

Campbell JM, O'Callaghan ME, Raymond E, Vincent AD, Beckmann KR, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, Borg M, Moretti KL.

Clin Genitourin Cancer. 2017 Dec;15(6):629-634.e8. doi: 10.1016/j.clgc.2017.03.011. Epub 2017 Mar 30. Review.

PMID:
28576416
40.

Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: A Systematic Review of Prognostic Tool Accuracy and Validity.

O'Callaghan ME, Raymond E, Campbell JM, Vincent AD, Beckmann K, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, Borg M, Moretti K.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):318-337. doi: 10.1016/j.ijrobp.2017.02.024. Epub 2017 Feb 21. Review.

PMID:
28463151
41.

An appraisal of analytical tools used in predicting clinical outcomes following radiation therapy treatment of men with prostate cancer: a systematic review.

Raymond E, O'Callaghan ME, Campbell J, Vincent AD, Beckmann K, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, Borg M, Moretti K.

Radiat Oncol. 2017 Mar 21;12(1):56. doi: 10.1186/s13014-017-0786-z. Review.

42.

Understanding c-MET signalling in squamous cell carcinoma of the head & neck.

Szturz P, Raymond E, Abitbol C, Albert S, de Gramont A, Faivre S.

Crit Rev Oncol Hematol. 2017 Mar;111:39-51. doi: 10.1016/j.critrevonc.2017.01.004. Epub 2017 Jan 12. Review.

PMID:
28259294
43.

Sixteen Years of Overregulation: Time to Unburden Mifeprex.

Mifeprex REMS Study Group, Raymond EG, Blanchard K, Blumenthal PD, Cleland K, Foster AM, Gold M, Grossman D, Pendergast MK, Westhoff CL, Winikoff B.

N Engl J Med. 2017 Feb 23;376(8):790-794. doi: 10.1056/NEJMsb1612526. No abstract available.

PMID:
28225670
44.

Novel TGF-β inhibitors ready for prime time in onco-immunology.

de Gramont A, Faivre S, Raymond E.

Oncoimmunology. 2016 Dec 7;6(1):e1257453. doi: 10.1080/2162402X.2016.1257453. eCollection 2017. Review.

45.

Serial multilevel urine pregnancy testing to assess medical abortion outcome: a meta-analysis.

Raymond EG, Shochet T, Blum J, Sheldon WR, Platais I, Bracken H, Dabash R, Weaver MA, Ngoc NTN, Blumenthal PD, Winikoff B.

Contraception. 2017 May;95(5):442-448. doi: 10.1016/j.contraception.2016.12.004. Epub 2016 Dec 29.

PMID:
28041991
46.

Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.

Vinik A, Bottomley A, Korytowsky B, Bang YJ, Raoul JL, Valle JW, Metrakos P, Hörsch D, Mundayat R, Reisman A, Wang Z, Chao RC, Raymond E.

Target Oncol. 2016 Dec;11(6):815-824.

PMID:
27924459
47.

Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.

Coriat R, Faivre SJ, Mir O, Dreyer C, Ropert S, Bouattour M, Desjardins R, Goldwasser F, Raymond E.

Int J Nanomedicine. 2016 Nov 21;11:6207-6216. eCollection 2016.

48.

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Faivre S, Niccoli P, Castellano D, Valle JW, Hammel P, Raoul JL, Vinik A, Van Cutsem E, Bang YJ, Lee SH, Borbath I, Lombard-Bohas C, Metrakos P, Smith D, Chen JS, Ruszniewski P, Seitz JF, Patyna S, Lu DR, Ishak KJ, Raymond E.

Ann Oncol. 2017 Feb 1;28(2):339-343. doi: 10.1093/annonc/mdw561.

PMID:
27836885
49.

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.

Riveiro ME, Astorgues-Xerri L, Vazquez R, Frapolli R, Kwee I, Rinaldi A, Odore E, Rezai K, Bekradda M, Inghirami G, D'Incalci M, Noel K, Cvitkovic E, Raymond E, Bertoni F.

Oncotarget. 2016 Dec 20;7(51):84675-84687. doi: 10.18632/oncotarget.13181.

50.

N-Arylsulfonyl-α-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.

Abeywardane A, Caviness G, Choi Y, Cogan D, Gao A, Goldberg D, Heim-Riether A, Jeanfavre D, Klein E, Kowalski JA, Mao W, Miller C, Moss N, Ramsden P, Raymond E, Skow D, Smith-Keenan L, Snow RJ, Wu F, Wu JP, Yu Y.

Bioorg Med Chem Lett. 2016 Nov 1;26(21):5277-5283. doi: 10.1016/j.bmcl.2016.09.047. Epub 2016 Sep 21.

Supplemental Content

Loading ...
Support Center